Expert Review of Clinical Immunology最新文献

Distinguishing the endotypes of Chronic rhinosinusitis: the emerging roles of macrophages. 鉴别慢性鼻窦炎的内源性：巨噬细胞的新作用。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-16 DOI: 10.1080/1744666X.2026.2747885

Zhibo Wang, Zhichen Liu, Ming Wang, Luo Zhang

{"title":"Distinguishing the endotypes of Chronic rhinosinusitis: the emerging roles of macrophages.","authors":"Zhibo Wang, Zhichen Liu, Ming Wang, Luo Zhang","doi":"10.1080/1744666X.2026.2747885","DOIUrl":"https://doi.org/10.1080/1744666X.2026.2747885","url":null,"abstract":"Introduction: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disorder characterized by different endotypes classically known as type 1/2/3 inflammation. Macrophages play a pivotal role in the pathogenesis of CRS. Under diverse inflammatory conditions, macrophages can polarize into different subsets and exert distinct functions across CRS endotypes. Recently, single-cell transcriptome analysis identified a series of macrophage subsets that have specific gene expression signatures associated with CRS endotypes.Areas covered: A literature search was conducted using PubMed with keywords 'CRS,' 'endotype,' and 'macrophage' and related terms, focusing on studies published over the past 10 years. This review dissects macrophage heterogeneity across CRS endotypes, summarizes how diverse stimulus factors shape macrophage states, and updates their roles under endotypes, providing clues for the development of macrophage-based biomarkers for endotyping and targeted therapy.Expert opinion: Effectively distinguishing CRS endotypes is meaningful for personalized therapies. An endotype-based interpretation of macrophage heterogeneity helps explain the divergent patterns of inflammation in CRS. In addition, the nasal tissue-resident macrophages attract growing interest as their contribution to olfactory loss in CRS.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":4.0,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The science-to-practice gap in allergology: a critical appraisal of determinants and knowledge-translation strategies across health systems. 过敏症学的科学与实践差距：对卫生系统中决定因素和知识转化战略的关键评估。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-15 DOI: 10.1080/1744666X.2026.2749713

Gabriele Di Lorenzo, Marcello Melluso, Riccardo De Carli, Aurelio Seidita

{"title":"The science-to-practice gap in allergology: a critical appraisal of determinants and knowledge-translation strategies across health systems.","authors":"Gabriele Di Lorenzo, Marcello Melluso, Riccardo De Carli, Aurelio Seidita","doi":"10.1080/1744666X.2026.2749713","DOIUrl":"10.1080/1744666X.2026.2749713","url":null,"abstract":"Introduction: Evidence-based medicine assumes that high-quality research, once produced, will reach the bedside. In allergology this assumption is repeatedly violated. Solid evidence accumulates while its uptake in daily practice remains incomplete and variable across health systems.Areas covered: This critical appraisal characterizes the science-to-practice gap in allergology using current data, drawn from a search of PubMed, MEDLINE, Embase, and the Cochrane Library covering January 2015 to March 2026. It examines the gap's determinants across institutional and economic contexts and evaluates knowledge-translation (KT) strategies with the strongest evidence base. ARIA, GINA, and EAACI adherence is quantified for allergic rhinitis, asthma, and AIT, with AIT uptake estimates treated as setting-specific rather than universal. Four determinant domains, education, conflicts of interest, reimbursement, and local adaptation, are compared across high-income EU countries, the UK, and low- and middle-income countries, and five KT strategies are appraised.Expert opinion: The gap is measurable, clinically consequential, and modifiable. Its persistence reflects structural and policy factors more than clinician knowledge. Combinations of audit-and-feedback and academic detailing, tailored to local environments and supported by clinical decision tools, offer the most durable improvement documented to date. Allergological societies should integrate implementation science and independent conflict-of-interest management into their strategic priorities.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-9"},"PeriodicalIF":4.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Parvovirus B19 and inflammatory arthritis: from viral mimicry to infection-associated autoimmunity. 细小病毒B19与炎性关节炎：从病毒模仿到感染相关自身免疫。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-15 DOI: 10.1080/1744666X.2026.2746700

Francesco Caso, Luisa Costa, Mario Cascone, Antonio Carleo, Francesco Maione, Giuliana Guggino, Roberto Giacomelli, Paola Cipriani, Federico Perosa, Piero Ruscitti

{"title":"Parvovirus B19 and inflammatory arthritis: from viral mimicry to infection-associated autoimmunity.","authors":"Francesco Caso, Luisa Costa, Mario Cascone, Antonio Carleo, Francesco Maione, Giuliana Guggino, Roberto Giacomelli, Paola Cipriani, Federico Perosa, Piero Ruscitti","doi":"10.1080/1744666X.2026.2746700","DOIUrl":"10.1080/1744666X.2026.2746700","url":null,"abstract":"Introduction: Parvovirus B19 is a clinically important viral mimic of systemic inflammatory rheumatic diseases, frequently presenting as an abrupt-onset inflammatory polyarthritis in adults. While typically self-limiting, B19V infection can induce transient autoantibodies, cytopenias, and phenotypes resembling rheumatoid arthritis or systemic lupus erythematosus. In specific contexts, it may also lead to persistent or atypical musculoskeletal manifestations.Areas covered: This narrative review summarizes the epidemiology, immunopathogenesis, clinical spectrum, diagnostic approach, and management of B19V-associated arthritis. Literature was identified through searches of PubMed/MEDLINE and relevant reference lists from inception to 23 September 2026, using terms related to parvovirus B19, arthritis, rheumatoid arthritis, autoimmunity, synovitis, cytokines, PCR, serology, and intravenous immunoglobulin.Expert opinion: B19V-associated arthritis should be recognized as a time-sensitive clinicovirological diagnosis, not merely a diagnosis of exclusion. Advancing the field requires prospective outbreak-based cohort studies, standardized diagnostic criteria, and the integration of virological and immunological biomarkers to distinguish self-limiting infection from evolving autoimmune disease.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-12"},"PeriodicalIF":4.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donidalorsen for the treatment of hereditary angioedema. 多尼达洛森治疗遗传性血管性水肿。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-15 DOI: 10.1080/1744666X.2026.2747222

Samantha R Horn, Bharosha Bhattarai, Timothy Craig

{"title":"Donidalorsen for the treatment of hereditary angioedema.","authors":"Samantha R Horn, Bharosha Bhattarai, Timothy Craig","doi":"10.1080/1744666X.2026.2747222","DOIUrl":"10.1080/1744666X.2026.2747222","url":null,"abstract":"Introduction: Hereditary angioedema (HAE) is a rare disorder with a prevalence of approximately 1 in 50,000. Management of HAE brings challenges, including the frequency of delivery of the medication, routes of medication delivery, cost of treatment and a significant impact on quality of life for patients with HAE. Donidalorsen is the newest FDA-approved long-term prophylaxis medication for HAE that offers substantial benefits over its competitors.Areas covered: A search of the current literature on donidalorsen was conducted using the PubMed and Cochrane libraries. In this review, we discuss the mechanism and clinical efficacy of donidalorsen. We also explore the comparison between donidalorsen and other agents on the market for the long-term prophylaxis of HAE. The safety profile of donidalorsen as well as a discussion on the economic impact of donidalorsen is also reviewed.Expert opinion: Donidalorsen offers a promising option for treatment of HAE, with substantial attack reduction, infrequent dosing, and improved quality of life. Continued long-term safety data are needed, but donidalorsen may become a leading prophylactic option for HAE worldwide.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-8"},"PeriodicalIF":4.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Approaches to identify patients with rheumatoid arthritis that should be screened for interstitial lung disease. 鉴别类风湿关节炎患者应筛查间质性肺疾病的方法

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-15 DOI: 10.1080/1744666X.2026.2748536

Natalie A Davis, Madeleine Y Beaulé, Jeffrey A Sparks

引用次数: 0

Mitochondria: a protector or culprit in lupus? 线粒体：狼疮的新罪魁祸首？

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-14 DOI: 10.1080/1744666X.2026.2747220

Andras Perl, Laurence Morel

引用次数: 0

Novel understanding in diagnosis and management of exercise-induced bronchoconstriction. 运动性支气管收缩诊断和治疗的新认识。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-14 DOI: 10.1080/1744666X.2026.2747863

John W Dickinson

{"title":"Novel understanding in diagnosis and management of exercise-induced bronchoconstriction.","authors":"John W Dickinson","doi":"10.1080/1744666X.2026.2747863","DOIUrl":"10.1080/1744666X.2026.2747863","url":null,"abstract":"Introduction: Exercise-induced bronchoconstriction (EIB) is a common cause of exercise-related respiratory symptoms in athletes and is traditionally diagnosed by demonstrating airway narrowing following exercise or surrogate bronchoprovocation testing. Whilst this provides objective evidence of bronchoconstriction, it offers limited insight into the underlying pathophysiology of airway dysfunction.Areas covered: This review discusses emerging developments in EIB, focusing on biomarkers of airway inflammation and injury, respiratory oscillometry, breathing pattern assessment and wearable respiratory monitoring. The concept that EIB may represent the clinical manifestation of a broader process of airway injury and remodeling is also considered. Relevant literature was identified through searches of PubMed and Google Scholar with no lower date restriction to May 2026, supplemented by reference-list searching.Expert opinion: The future challenge in EIB is no longer simply confirming bronchoconstriction but identifying athletes at risk of airway dysfunction before clinically significant disease develops. Emerging biomarkers, oscillometry and continuous respiratory monitoring may enable earlier phenotyping and more personalized management than conventional bronchoprovocation testing alone. Collectively, these approaches have the potential to shift EIB care from diagnosing established disease toward preserving airway health within a holistic model of athlete respiratory care.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":4.0,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular HLA matching in kidney transplantation: the emerging role of eplet mismatch analysis. HLA分子匹配在肾移植中的作用：基因不匹配分析的新作用。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-14 DOI: 10.1080/1744666X.2026.2749714

Simmi Mehra, Rajni Chauhan, Aseem Kumar Tiwari, Vyas M Shingatgeri, Gunjan Bhardwaj, Shubham Gupta, Simran Kahlon, Punit Kumar

{"title":"Molecular HLA matching in kidney transplantation: the emerging role of eplet mismatch analysis.","authors":"Simmi Mehra, Rajni Chauhan, Aseem Kumar Tiwari, Vyas M Shingatgeri, Gunjan Bhardwaj, Shubham Gupta, Simran Kahlon, Punit Kumar","doi":"10.1080/1744666X.2026.2749714","DOIUrl":"https://doi.org/10.1080/1744666X.2026.2749714","url":null,"abstract":"Introduction: Kidney transplantation is the preferred treatment for end-stage kidney disease, but long-term graft survival remains limited by alloimmune injury, particularly donor-specific antibody-mediated rejection. This review evaluates molecular HLA matching as an approach to improve donor-recipient compatibility assessment beyond conventional antigen-level matching.Areas covered: The biological basis of HLA epitopes and eplets is described, with emphasis on HLAMatchmaker, HLA-EMMA, PIRCHE-II, and related computational approaches. Evidence linking molecular mismatch with de novo donor-specific antibodies, antibody-mediated rejection, chronic allograft injury, and graft survival is reviewed. Qualitative eplet immunogenicity, structural accessibility, amino-acid properties, antibody verification, and HLA-DQ-associated risk are also examined. A literature search was conducted using PubMed/MEDLINE and Scopus, focusing on studies published during the preceding 10 years, employing terms related to kidney transplantation, HLA eplet mismatch, molecular HLA matching, donor-specific antibodies, rejection, and graft outcomes.Expert opinion: HLA eplet-based matching may improve immunological risk stratification and individualized surveillance. However, algorithmic variability, incomplete antibody verification, differences in HLA typing resolution, population limitations, and lack of standardized thresholds restrict implementation. Prospective multi-center studies are needed to establish clinical utility, cost-effectiveness, and whether molecularly informed donor selection or monitoring improves patient and graft outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation. GLP-1受体激动剂在中枢神经系统疾病中的治疗潜力：免疫细胞调节和神经炎症。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-13 DOI: 10.1080/1744666X.2026.2747225

Ziyu Wang, Song Xue, Xin Zhou, Mengyao Yuan, Xin Sun

{"title":"The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.","authors":"Ziyu Wang, Song Xue, Xin Zhou, Mengyao Yuan, Xin Sun","doi":"10.1080/1744666X.2026.2747225","DOIUrl":"10.1080/1744666X.2026.2747225","url":null,"abstract":"Introduction: Central nervous system (CNS) diseases impose a substantial global burden; however, effective treatments remain limited. Neuroinflammation contributes to the development and progression of various CNS diseases. Preclinical evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may alleviate neuroinflammation by modulating immune cell-related processes, showing therapeutic potential in CNS diseases.Areas covered: We searched PubMed/MEDLINE, Embase, and Web of Science for literature published between 2016 and 2026. We summarize preclinical evidence that various GLP-1RAs alleviate neuroinflammation across different CNS diseases through modulation of peripheral and central immune cells, focusing on neutrophils, monocytes/macrophages, T lymphocytes, microglia, astrocytes, and their crosstalk, and discuss related clinical translation and challenges.Expert opinion: Repurposing GLP-1RAs, including exenatide, liraglutide, semaglutide, and dulaglutide, may provide a therapeutic option for CNS diseases. However, most mechanistic evidence remains preclinical, and clinical efficacy has not been established. Future studies should integrate neuroimmune biomarkers with clinical outcomes to determine whether immunomodulatory effects translate into clinical benefit. Future research should also distinguish direct CNS effects from peripheral metabolic effects across different GLP-1RAs and identify appropriate patient populations. The effects of age, sex, comorbidities, and concomitant medications on efficacy and safety, as well as potential adverse effects of long-term use, also warrant attention.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-22"},"PeriodicalIF":4.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transient hypogammaglobulinemia of infancy: revisiting an old entity. 婴儿短暂性低γ -球蛋白血症：重访一个旧实体。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-10-04 DOI: 10.1080/1744666X.2026.2742255

Zehra Genç Ozbay, Saliha Esenboga

{"title":"Transient hypogammaglobulinemia of infancy: revisiting an old entity.","authors":"Zehra Genç Ozbay, Saliha Esenboga","doi":"10.1080/1744666X.2026.2742255","DOIUrl":"https://doi.org/10.1080/1744666X.2026.2742255","url":null,"abstract":"Introduction: Transient hypogammaglobulinemia of infancy (THI) is one of the most common primary antibody deficiencies presenting in early childhood and is characterized by delayed maturation of humoral immunity with spontaneous normalization of immunoglobulin G (IgG) levels in most patients. Although THI has traditionally been considered a benign, self-limited disorder, increasing evidence suggests that it represents a heterogeneous immunologic condition with variable clinical manifestations, immune abnormalities, and long-term outcomes.Areas covered: This narrative review summarizes evidence identified through PubMed/MEDLINE searches from database inception to July 2026 using terms related to THI, supplemented by manual screening of reference lists. Clinical manifestations range from asymptomatic disease to recurrent respiratory tract infections, wheezing, otitis media, sinusitis, atopic disease, and, less commonly, autoimmune or inflammatory complications. A major clinical challenge is differentiating THI from persistent primary antibody deficiencies, particularly common variable immunodeficiency, during early childhood. Because definitive diagnosis can only be established retrospectively after normalization of immunoglobulin levels, careful longitudinal clinical and immunologic follow-up remains essential.Expert opinion: Advances in immunophenotyping and molecular profiling are improving our understanding of THI pathogenesis and may facilitate the identification of biomarkers that distinguish transient immune delay from evolving primary immunodeficiency, supporting earlier diagnosis and more individualized follow-up.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-9"},"PeriodicalIF":4.0,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0